The Global Market for Rheumatoid Arthritis Drugs (2018-2022): Analysis by Type of Molecule, Type of RA, Region and Vendor

DUBLIN, Dec 7, 2018 /PRNewswire/ --

The "Global Rheumatoid Arthritis Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.

The use of biologics and biosimilars for the treatment of RA is likely to help the market grow. Unlike synthetic DMARDs, biologics have targeted mechanisms of action and serve as promising molecules for the successful treatment of RA.

Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumatoid arthritis.

Social stigma associated with RA mainly due to physical deformities and functional limitations in RA patients. Various strategies are being adopted to tackle social stigma at the patient level.

Market Trends

Key Players

• High cost of RA drugs
• Use of biologics/biosimilars for treatment of RA
• Use of gene therapy for RA treatment
• Market dominance by TNF-alpha inhibitors
• Need for rheumatologists

• AbbVie
• Amgen
• Johnson & Johnson
• Novartis
• Pfizer
• UCB Pharma

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 05: PIPELINE ANALYSIS

• Pipeline analysis

PART 06: MARKET SIZING

• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: MARKET SEGMENTATION BY TYPE OF MOLECULE

• Segmentation by type of molecule
• Comparison by type of molecule
• Biologics - Market size and forecast 2017-2022
• Small molecules - Market size and forecast 2017-2022
• Market opportunity by type of molecule

PART 09: MARKET SEGMENTATION BY TYPE OF RA

• Segmentation by type of RA
• Seropositive RA
• Seronegative RA

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

• Geographical segmentation
• Regional comparison
• Americas - Market size and forecast 2017-2022
• EMEA - Market size and forecast 2017-2022
• APAC - Market size and forecast 2017-2022
• Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 14: MARKET TRENDS

• High cost of RA drugs
• Use of biologics/biosimilars for treatment of RA
• Use of gene therapy for RA treatment
• Market dominance by TNF-alpha inhibitors
• Need for rheumatologists

PART 15: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 16: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• AbbVie
• Amgen
• Johnson & Johnson
• Novartis
• Pfizer
• UCB Pharma

For more information about this report visit https://www.researchandmarkets.com/research/l545p8/the_global_market?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/the-global-market-for-rheumatoid-arthritis-drugs-2018-2022-analysis-by-type-of-molecule-type-of-ra-region-and-vendor-300761866.html

SOURCE Research and Markets